文献速递青光眼

青光眼手术失败后睫状体上腔支架植入的安全性与疗效

The Safety and Efficacy of Supraciliary Stenting Following Failed Glaucoma Surgery.
PubMed 文献 · Am J Ophthalmol · 2018-04-09

本研究为介入性病例系列,纳入20例既往青光眼手术失败的难治性青光眼患者,行内路睫状体上腔微支架(CyPass Micro-Stent)植入。12个月时平均眼压从基线22.5±8.0 mmHg降至14.9±4.3 mmHg(降低33.7%,P=.01),平均用药从2.7±1.0种减少56%至1.2±1.5种(P=.01)。无严重术中并发症或重大不良事件,结论认为该术式安全性良好且能有效控制眼压、减少用药负担。

要点

  • 12个月平均眼压从22.5±8.0 mmHg降至14.9±4.3 mmHg,降低33.7%(P=.01)。
  • 平均用药从2.7±1.0种减少56%至1.2±1.5种(P=.01)。
  • 无严重术中并发症或重大不良事件,2例(10%)后续需植入水引流管。

核心结论

  • 内路睫状体上腔支架植入安全性良好,对既往青光眼手术失败眼可有效控制眼压并减少用药负担。

研究设计与样本

  • 介入性病例系列,地点为英国伦敦Moorfields眼科医院,纳入20例既往青光眼手术失败的难治性青光眼患者的20只眼。
  • 干预为内路睫状体上腔微支架(CyPass Micro-Stent;Alcon,美国德克萨斯州Fort Worth)植入。
  • 主要结局指标包括眼部不良事件发生、平均眼压变化及至12个月的青光眼用药情况。

主要发现

  • 基线平均眼压为22.5±8.0 mmHg,平均用药数为2.7±1.0种;多数患者既往接受过小梁切除术或水引流管手术。
  • 无严重术中并发症或睫状体上腔支架植入后重大不良事件。
  • 最常见不良事件为暂时性前房积血(3/20,15%)、暂时性眼压>30 mmHg(4/20,20%)和暂时性眼压<6 mmHg(4/20,20%)。
  • 12个月时平均眼压为14.9±4.3 mmHg,较基线降低33.7%(P=.01)。
  • 12个月时平均用药减少56%至1.2±1.5种(P=.01);2例患者(10%)需后续植入水引流管。

临床怎么用

  • 原文结论认为,内路睫状体上腔支架植入安全性良好,是既往青光眼手术失败眼控制眼压和减少用药负担的有效方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of supraciliary stenting following failed glaucoma surgery. DESIGN: Interventional case series. METHODS: Setting: Moorfields Eye Hospital, London, United Kingdom. STUDY POPULATION: Twenty eyes from 20 patients with glaucoma refractory to prior glaucoma surgery. INTERVENTION: Ab interno microstent (CyPass Micro-Stent; Alcon, Fort Worth, Texas, USA) implantation into the supraciliary space. MAIN OUTCOME MEASURES: Outcome measures included the occurrence of ocular adverse events, mean intraocular pressure (IOP) change, and glaucoma medication use through 12 months. RESULTS: Mean baseline IOP was 22.5 ± 8.0 mm Hg and number of medications was 2.7 ± 1.0. The majority of patients had undergone either prior trabeculectomy or aqueous shunt surgery. There were no serious intraoperative complications or major adverse events following supraciliary stenting. The most common adverse events included transient hyphema (3/20, 15%), transient IOP > 30 mm Hg (4/20, 20%), and transient IOP < 6 mm Hg (4/20, 20%). At 12 months, mean IOP was 14.9 ± 4.3 mm Hg-a 33.7% reduction (P = .01). Mean medication usage decreased 56% to 1.2 ± 1.5 at 12 months (P = .01). Two patients (10%) required subsequent aqueous shunt insertion. CONCLUSION: Ab interno supraciliary stenting has a favorable safety profile and provides an effective approach to controlling IOP and reducing medication burden in eyes in which previous glaucoma surgery has failed.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Kerr NM, Wang J, Perucho L, et al. The Safety and Efficacy of Supraciliary Stenting Following Failed Glaucoma Surgery. Am J Ophthalmol. 2018. PMID: 29649424. doi:10.1016/j.ajo.2018.03.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。